Arvinas (ARVN) Operating Income (2017 - 2026)
Arvinas (ARVN) recorded quarterly Operating Income of -$63.8 million in Q1 2026, up 14.48% quarter-over-quarter from -$74.6 million in Q4 2025, and down 189.36% on a YoY basis from $71.4 million in Q1 2025.
Arvinas (ARVN) Operating Income (2017 - 2026) Analysis & Trends
Arvinas' Operating Income history runs 10 years deep, the most recent figure standing at -$63.8 million for Q1 2026.
- In Q1 2026, Operating Income fell 189.36% year-over-year to -$63.8 million; the TTM figure through Mar 2026 stood at -$253.7 million (down 165.38% YoY), while the FY2025 annual figure was -$118.5 million, up 52.64% from the prior year.
- Operating Income was -$63.8 million for Q1 2026 at Arvinas, up from -$74.6 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $71.4 million in Q1 2025 to a low of -$165.3 million in Q4 2023.
- Historically, Operating Income has averaged -$64.6 million across 5 years, with a median of -$65.8 million in 2022.
- The sharpest annual moves came in 2025 and 2026: Operating Income surged 185.71% in 2025, then slumped 189.36% in 2026.
- A 5-year view of Operating Income shows it stood at -$75.6 million in 2022, then plunged by 118.65% to -$165.3 million in 2023, then soared by 64.79% to -$58.2 million in 2024, then decreased by 28.18% to -$74.6 million in 2025, then advanced by 14.48% to -$63.8 million in 2026.
- The last three Operating Income figures came in at -$63.8 million (Q1 2026), -$74.6 million (Q4 2025), and -$43.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | -63.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.80 Mn |
| Dec 31, 2025 | -74.60 Mn |
| Sep 30, 2025 | -43.80 Mn |
| Jun 30, 2025 | -71.50 Mn |
| Mar 31, 2025 | 71.40 Mn |
| Dec 31, 2024 | -58.20 Mn |
| Sep 30, 2024 | -60.30 Mn |
| Jun 30, 2024 | -48.50 Mn |
| Mar 31, 2024 | -83.30 Mn |
| Dec 31, 2023 | -165.30 Mn |
| Sep 30, 2023 | -73.90 Mn |
| Jun 30, 2023 | -74.60 Mn |
| Mar 31, 2023 | -87.70 Mn |
| Dec 31, 2022 | -75.60 Mn |
| Sep 30, 2022 | -64.30 Mn |
| Jun 30, 2022 | -65.80 Mn |
| Mar 31, 2022 | -57.70 Mn |
| Dec 31, 2021 | -47.50 Mn |
| Sep 30, 2021 | -47.30 Mn |
| Jun 30, 2021 | -51.90 Mn |